Masimo (NASDAQ:MASI) Updates FY 2020 Pre-Market Earnings Guidance

Masimo (NASDAQ:MASI) updated its FY 2020
Pre-Market earnings guidance on Tuesday. The company provided earnings per share guidance of 3.56-3.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.56. The company issued revenue guidance of $1.035-1.035 billion, compared to the consensus revenue estimate of $1.04 billion.Masimo also updated its FY 2019
Pre-Market guidance to 3.18 EPS.

Several brokerages have issued reports on MASI. UBS Group raised their price objective on shares of Masimo from $180.00 to $190.00 and gave the stock a buy rating in a research report on Wednesday. ValuEngine cut shares of Masimo from a buy rating to a hold rating in a research note on Wednesday, October 2nd. Piper Sandler restated a buy rating and issued a $175.00 target price on shares of Masimo in a research note on Wednesday. BidaskClub upgraded shares of Masimo from a hold rating to a buy rating in a research note on Monday, December 16th. Finally, Piper Jaffray Companies restated an overweight rating and issued a $175.00 target price (up previously from $161.00) on shares of Masimo in a research note on Tuesday, December 17th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $165.07.

Shares of MASI stock traded up $1.33 during mid-day trading on Thursday, hitting $169.45. The stock had a trading volume of 3,289 shares, compared to its average volume of 304,037. Masimo has a fifty-two week low of $115.72 and a fifty-two week high of $167.87. The firm has a market cap of $8.75 billion, a PE ratio of 55.81, a PEG ratio of 2.00 and a beta of 1.13. The company’s 50-day simple moving average is $158.24 and its 200-day simple moving average is $152.15.

Masimo (NASDAQ:MASI) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $0.76 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.03. Masimo had a net margin of 20.83% and a return on equity of 17.32%. The company had revenue of $229.01 million during the quarter, compared to analysts’ expectations of $221.92 million. During the same quarter last year, the business earned $0.71 EPS. The business’s revenue was up 8.8% on a year-over-year basis. Research analysts expect that Masimo will post 3.18 earnings per share for the current fiscal year.

In related news, EVP Thomas Samuel Mcclenahan sold 500 shares of the firm’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $159.29, for a total value of $79,645.00. Following the completion of the sale, the executive vice president now owns 5,607 shares in the company, valued at $893,139.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sanford Fitch sold 6,500 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $147.08, for a total transaction of $956,020.00. Following the completion of the sale, the director now owns 50,745 shares of the company’s stock, valued at approximately $7,463,574.60. The disclosure for this sale can be found here. Insiders sold 56,000 shares of company stock valued at $8,683,715 in the last quarter. Company insiders own 11.50% of the company’s stock.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Article: What does an equal weight rating mean?

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with's FREE daily email newsletter.